Neurol. praxi. 2019;20(6):439-442
Secondary progressive multiple sclerosis: therapeutic nihilism or active approach?
- MS centrum při Neurologickém oddělení KZ, a. s. – Nemocnice Teplice, o. z., Teplice
In secondary progressive multiple sclerosis (SPRS), such convincing therapeutic successes cannot be achieved as in relapsing disease. However, rapid initiation of effective treatment in the early stages of the disease slows the development of secondary progression. In active SPRS we use the immunosuppressive potential of mitoxantrone, cyclophosphamide eventually high doses of methylprednisolone and intravenous immunoglobulin. Siponimod is the first approved drug in the SPRS indication, which has been shown to slow clinically confirmed progression. At the stage of clinical trials, other drugs are predominantly neuroprotective.
Keywords: secondary progressive multiple sclerosis, therapy, siponimod, neuroprotection
Published: December 1, 2019 Show citation
